Category: C
Royal Mail 2nd Class / Parcel Force 48
UK to UK :Normally arrives in 2-4 business days.
UK to Ireland :Normally arrives in 4-6 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note standered delivery is none trackable , none insured , no responsabily for lose or Damage
----------------------------------------------------------------------------------------------------------------
Royal Mail First Class / Parcel Force 24
UK to UK :Normally arrives in 1-2 business days.
UK to Ireland 3-4 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note :Trackable , Royal Mail insured up to £50.
--------------------------------------------------------------------------------------------------------
Parcel Force Express AM Guaranteed before Midday.
UK to UK only . UP to 5KG Max Weight
Arrives next day before 12 noon, requires a signature.
Parcel Forcel Terms & Conditions apply
Important: Parcel Force advise that there are some postcodes where an extended delivery time exists, and may affect the date of delivery or the service is not available.
| Category | POM-VPS |
| Temperature | Ambient |
| MA/VM/EU No: | 42058/4031 |
| Species |
|
| VMD Link | https://www.vmd.defra.gov.uk/ProductInformationDatabase/product/A008041 |
| NOAH Link | https://www.noahcompendium.co.uk/?id=-456853&fromsearch=true#iosfirsthighlight |
| Dosage | For external use only. 0.5 mg moxidectin/kg bodyweight and 20 mg triclabendazole/kg bodyweight, equivalent to 1 ml per 10 kg, as a single topical application. To be administered directly to the hair and skin along the midline of the back of the animal from the withers to the tail head. Apply to clean healthy skin. To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device should be checked. If animals are to be treated collectively rather than individually, they should be grouped according to their bodyweight and dosed accordingly, in order to avoid under- or over-dosing. Shake before use. Directions for using the Squeeze-Pour System (500 ml and 1 litre bottles only): •Step 1: Remove screw cap from dispensing chamber only. Remove foil seal. •Step 2: Gently squeeze the bottle to fill the measuring chamber with the required amount of liquid. •Step 3: Pour the measured volume of fluid from the chamber onto the animal as directed. •Repeat steps 2 and 3 for subsequent animals. •Step 4: Reapply the screw cap to the dispensing chamber after use. Description: h-751 Directions for using a pour-on applicator (2.5 and 5 litre backpack): •Connect the pour-on applicator to the backpack as follows: •Attach the open end of the draw-off tubing to the cap with the stem. •Replace shipping cap with the cap that has the draw-off tubing. Tighten the draw-off cap. •Gently prime the pour-on applicator, checking for leaks. •Follow manufacturer’s directions for correct use and care of equipment. |
| Withdrawals | Do not use in cases of hypersensitivity to the active substance(s) or to any of the excipient(s). Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: •Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. •Under-dosing, which may be due to underestimation of bodyweight, misadministration of the product, or lack of calibration of the dosing device (if any). Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used. Resistance to moxidectin has been reported mainly in Cooperia oncophora in some European countries. Resistance to other MLs in some strains of Cooperia spp. can imply concurrent resistance to Moxidectin. Resistance to triclabendazole has been reported in Fasciola hepatica in cattle in some European countries. Triclabendazole resistant F. hepatica hosted in sheep can be transferred to cattle grazing the same pasture. Therefore the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of parasites, local history of treatments and recommendations on how to limit further selection for resistance to anthelmintics. CYDECTIN TriclaMox should not be used for the treatment of single infections. It has been shown that rainfall immediately before or within 2 hours after treatment will not affect the efficacy of the product. Digestive tract disorders such as diarrhoea, neurological disorders such as ataxia, hypersensitivity/allergic reactions and skin irritation at the application site may be observed very rarely (less than 1 animal in 10,000 animals treated, including isolated reports). In the absence of compatibility studies, CYDECTIN TriclaMox must not be mixed with other veterinary medicinal products. Signs of overdoses have not been seen 5 times the recommended dose. However, if they do occur they should be consistent with the mode of action of moxidectin and would be manifested as transient salivation, depression, drowsiness and ataxia. Treatment is not generally necessary and recovery is generally complete within 24 to 48 hours. There is no specific antidote. CYDECTIN TriclaMox is safe for use in pregnant and lactating animals. CYDECTIN TriclaMox has been formulated specifically for pour-on administration for cattle and must not be given by any other route of administration or to any other species. Withdrawal period Meat and offal: 143 days Milk: Do not use in cattle of any age intended to produce milk for human consumption. Due to the significant likelihood of cross-contamination of non-treated animals with this product due to grooming (licking), treated animals should be housed separately from non-treated animals throughout the withdrawal period. Non-compliance with this recommendation may lead to residues violations in non-treated animals. Operator warning People with known hypersensitivity to the active substances should not handle the product. This product may cause skin and eye irritation. Avoid direct contact with skin and eyes. Wear gloves, protective work clothing and safety glasses when using the product. If splashed in the eye or on the skin, wash with plenty of clean, running water immediately. If irritation persists, seek medical advice and show the label to the doctor. Do not smoke, drink or eat while handling the product. Wash hands after use. Other precautions regarding impact on the environment Moxidectin fulfils the criteria for a (very) persistent, bioaccumulative and toxic (PBT) substance; therefore, exposure of the environment to moxidectin must be limited to the extent possible. Treatments should be administered only when necessary and should be based on faecal egg counts or evaluation of the risk of infestation at the animal and/or herd level. Like other macrocyclic lactones, moxidectin has the potential to adversely affect non-target organisms: •Faeces containing moxidectin excreted onto pasture by treated animals may temporarily reduce the abundance of dung feeding organisms. Following treatment of cattle with the product, levels of moxidectin that are potentially toxic to dung fly species may be excreted over a period more than 2 weeks and may decrease dung fly abundance during that period. It has been established in laboratory tests that moxidectin may temporarily affect dung beetle reproduction; however, field studies indicate no-long term effects. Nevertheless, in case of repeated treatments with moxidectin (as with products of the same anthelmintic class) it is advisable not to treat animals every time on the same pasture to allow dung fauna populations to recover. •Moxidectin is inherently toxic to aquatic organisms including fish. The product should be used only according to the label instructions. Based on the excretion profile of moxidectin when administered as the pour-on formulation, treated animals should not have access to watercourses during the first week after treatment. |
